Headquartered in Rockaway, NJ Fiscal year ends December NASDAQ: ECOR electrocore.com
electroCore, Inc. is a bioelectronic technology company focused on improving health outcomes through non-invasive bioelectronic technologies. Its prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device indicated for the treatment of primary headache conditions, and Quell Fibromyalgia, acquired from NeuroMetrix in May 2025. The company also commercializes Truvaga, a handheld general wellness nVNS product sold direct-to-consumer, and TAC-STIM, an nVNS product for general wellness and human performance. The U.S. Department of Veterans Affairs is the company's largest sales channel, with a growing presence in the Department of Defense and Kaiser Permanente systems. The company sells its products through a combination of direct sales, 1099 contract representatives, and federal procurement channels including Lovell Government Services as its primary Federal Supply Schedule contract holder. Updated
Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing,…
Jon C. Ogg electroCore, Inc. is a bioelectronic technology company focused on improving health outcomes through non-invasive bioelectronic technologies.
The Wall Street consensus 12-month price target for ECOR is $19.17.